20077 ⎘
Medicinal preparations characterised by special physical form; Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles; Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
Orally effective methylphenidate extended release powder and aqueous suspension product
#1202Solid pharmaceutical dispersions with enhanced bioavailability
#1203Active Agent Formulations, Methods of Making, and Methods of Use
#1204EPINEPHRINE NANOPARTICLES, METHODS OF FABRICATION THEREOF, AND METHODS FOR USE THEREOF FOR TREATMENT OF CONDITIONS RESPONSIVE TO EPINEPHRINE
#1205Pharmaceutical compositions of semi-ordered drugs and polymers
#1206INJECTABLE NANOPARTICULATE OLANZAPINE FORMULATIONS
#1207Pharmaceutical composition for the treatment of acute disorders
#1208Pharmaceutical composition for the treatment of acute disorders
#1209ORAL FORM OF ADMINISTRATION COMPRISING ENTECAVIR
#1210Pharmaceutical compositions of dispersions of amorphous drugs mixed with polymers
#1211Solid pharmaceutical dispersions with enhanced bioavailability
#1212Process for forming amorphous atorvastatin
#1213Pharmaceutical compositions comprising colloidal silicon dioxide
#1214Solid pharmaceutical dispersions with enhanced bioavailability
#1215COMPOSITIONS AND METHODS OF DELIVERY OF PHARMACOLOGICAL AGENTS
#1216Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
#1217SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT
#1218Nucleic acid-containing lipid particles and related methods
#1219METHOD FOR MANUFACTURING ACID PELLETS
#1220Collagen matrix for tissue engineering
#1221Drug loaded polymeric nanoparticles and methods of making and using same
#1222Chemoembolisation
#1223Pharmaceutical compositions with enhanced performance
#1224Aqueous suspensions of submicron 9-hydroxyrisperidone fatty acid esters
#1225EMERGENCY CONTRACEPTIVE
#1226NOVEL FORMULATION OF METAXALONE
#1227Methods and systems for generating nanoparticles
#1228Pharmaceutical compositions providing enhanced drug concentrations
#1229Pharmaceutical Composition and Administrations Thereof
#1230Solid compositions
#1231Implantable polymeric device for sustained release of dopamine agonist
#1232Delivery system for sustained release of a calcium-channel blocking agent
#1233Solid dispersion formulations and methods of use thereof
#1234PHARMACEUTICAL COMPOSITION CONTAINING MEDICAMENT-CONTAINING FINE PARTICLES AND METHOD FOR PRODUCING SAME
#1235Fragmented hydrogels
#1236SOLID PHARMACEUTICAL COMPOSITIONS CONTAINING PREGABALIN
#1237Galenic form suitable for absorbing, in a specific manner, the undesirable molecules in the digestive tract
#1238SUSTAINED RELEASE CANNABINOID MEDICAMENTS
#1239PHARMACEUTICAL COMPOSITIONS COMPRISING RIVAROXABAN
#1240Block Copolymer For Intraperitoneal Administration Containing Anti-Cancer Agent, Micelle Preparation Thereof, And Cancer Therapeutic Agent Comprising The Micelle Preparation As Active Ingredient
#1241VACCINE FORMULATION OF MANNOSE COATED PEPTIDE PARTICLES
#1242Cellulose-based nanoparticles for drug delivery
#1243DRY POWDER AEROSOLS OF NANOPARTICULATE DRUGS
#1244PROCESS FOR CONTROLLED CRYSTALLIZATION OF AN ACTIVE PHARMACEUTICAL INGREDIENT FROM SUPERCOOLED LIQUID STATE BY HOT MELT EXTRUSION
#1245DRUG DELIVERY SYSTEMS (WAFER) FOR PEDIATRIC USE
#1246Orally effective methylphenidate extended release powder and aqueous suspension product
#1247Rapidly Soluble Solid Pharmaceutical Preparations Containing Amphiphilic Copolymers Based On Polyethers In Combination With Hydrophilic Polymers
#1248METHODS AND COMPOSITIONS FOR DETERRING ABUSE OF ORALLY ADMINISTERED PHARMACEUTICAL PRODUCTS
#1249DRUG FORMULATIONS
#1250Compositions controlling pH range of release and/or release rate
#1251PRODUCTION OF ENCAPSULATED NANOPARTICLES AT COMMERCIAL SCALE
#1252Composition Comprising S-Allyl-L-Cysteine as Active Ingredient for Preventing or Treating Gastrointestinal Disorders
#1253Highly stable compositions of orally active nucleotide analogues or orally active nucleotide analogue prodrugs
#1254Anionic-core composition for delivery of therapeutic agents, and methods of making and using the same
#1255CO-PRECIPITATE COMPRISING A PHOSPHODIESTERASE-5 INHIBITOR (PDE-5-INHIBITOR) AND A PHARMACEUTICALLY COMPATIBLE CARRIER, PRODUCTION AND USE THEREOF
#1256FLAVONOL COMPOSITIONS
#1257METHODS OF ADMINISTERING LIQUID DROPLET AEROSOLS OF NANOPARTICULATE DRUGS
#1258Solid Pharmaceutical Preparations Comprising Amphiphilic Copolymers On The Basis Of Polyethers In Combination With Surfactants
#1259Co-Processed Excipient Compositions
#1260FORMULATION COMPRISING FENOFIBRIC ACID, A PHYSIOLOGICALLY ACCEPTABLE SALT OR DERIVATIVE THEREOF
#1261Use of a copolymer in the form of a solubiliser for a poorly water-soluble compound
#1262Combinations and modes of administration of therapeutic agents and combination therapy
#1263Oxaliplatin nanoparticles and method for preparing same
#1264PRODUCTION OF ENCAPSULATED NANOPARTICLES AT HIGH VOLUME FRACTIONS
#1265METHOD FOR IMPROVING THE DISSOLUTION PROFILE OF A BIOLOGICALLY ACTIVE MATERIAL
#1266Pharmaceutical composition of duloxetine
#1267Nanoparticle isoflavone compositions and methods of making and using the same
#1268METHOD FOR THE PRODUCTION OF COMMERCIAL NANOPARTICLE AND MICRO PARTICLE POWDERS
#1269ORAL FORMULATIONS OF BENDAMUSTINE
#1270ANTIOXIDANTS IN FISH OIL POWDER AND TABLETS
#1271Prasugrel in non-crystalline form and pharmaceutical composition thereof
#1272TESTOSTERONE UNDECANOATE COMPOSITIONS
#1273NANOPARTICULATE OLMESARTAN MEDOXOMIL COMPOSITIONS, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
#1274NOVEL FORMULATION OF NAPROXEN
#1275PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CANCER
#1276Polymer formulations for delivery of bioactive materials
#1277NANOPARTICULATE CANDESARTAN CILEXITIL COMPOSITIONS, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
#1278NOVEL FORMULATION OF MELOXICAM
#1279Therapeutic polymeric nanoparticle compositions with high glass transition temperature or high molecular weight copolymers
#1280HYDROPHOBINS FOR DISPERSING ACTIVE AGENTS
#1281NANOPARTICULATE TELMISARTAN COMPOSITIONS AND PROCESS FOR THE PREPARATION THEREOF
#1282NOVEL FORMULATION OF INDOMETHACIN
#1283Formulation of diclofenac
#1284STABLE DRY POWDER COMPOSITION COMPRISING BIOLOGICALLY ACTIVE MICROORGANISMS AND/OR BIOACTIVE MATERIALS AND METHODS OF MAKING
#1285PHARMACEUTICAL COMPOSITIONS FOR POORLY SOLUBLE DRUGS
#1286NANOPARTICULATE BISPHOSPHONATE COMPOSITIONS
#1287Nanoparticle isoflavone compositions and methods of making and using the same
#1288Novel mometasone compositions and methods of making and using the same
#1289RAPIDLY DISINTEGRATING SOLID ORAL DOSAGE FORM
#1290PHARMACEUTICAL COMPOSITION 271
#1291Aerosol-mediated particle synthesis
#1292Pharmaceutical microparticles
#1293Coenzyme Q10-containing composition
#1294MATERIAL AND PROCESS FOR INCORPORATION OF LOW DOSAGE ACTIVE PHARMACEUTICAL INGREDIENTS AND USE THEREOF
#1295TASTE-MASKED ORAL FORMULATIONS OF INFLUENZA ANTIVIRALS
#1296STABILIZATION OF CHEMICAL COMPOUNDS USING NANOPARTICULATE FORMULATIONS
#1297NANOPARTICULATE MEGESTROL FORMULATIONS
#1298Pharmaceutical Compositions
#1299SURFACE-TREATED MODAFINIL PARTICLES
#1300FORMULATIONS OF RIFAXIMIN AND USES THEREOF
#1301NANOPARTICULATE STABILIZED ANTI-HYPERTENSIVE COMPOSITIONS
#1302Compositions, methods, and systems relating to controlled crystallization and/or nucleation of molecular species
#1303Substituted 6-(Benzylamino) Purine Riboside Derivatives, Use Thereof and Compositions Containing These Derivatives
#1304Methods of treating cancer
#1305Submicron Particles of Antineoplastic Agents
#1306Rhein or diacerein compositions
#1307Dry powder fibrin sealant
#1308Modified-release pharmaceutical drug composition
#1309NOVEL NIMESULIDE COMPOSITIONS
#1310NANOPARTICULATE COMPOSITIONS OF POORLY SOLUBLE COMPOUNDS
#1311Branched Polyesters Based On Citric Acid, Their Preparation And Use
#1312SOLID RETIGABINE IN NON-CRYSTALLINE FORM
#1313Compositions and methods for loop diuretics with consistent bioavailability
#1314Liquid ganaxolone formulations and methods for the making and use thereof
#1315FORMULATION COMPRISING FENOFIBRIC ACID, A PHYSIOLOGICALLY ACCEPTABLE SALT OR DERIVATIVE THEREOF
#1316INTERMEDIATE AND ORAL ADMINISTRATIVE FORMATS CONTAINING LENALIDOMIDE
#1317Policosanol nanoparticles
#1318Coenzyme Q10 nanoparticles, preparation method thereof and composition containing said nanoparticles
#1319Photo-Crosslinked Nucleic Acid Hydrogels
#1320Offshore fluid offloading systems and methods
#1321EXTRUDATE HAVING SPICULAR ACTIVE SUBSTANCES
#1322Method of controlling the release of an active ingredient from a dosage form
#1323Solid Pharmaceutical Compositions Containing Pregabalin
#1324PHARMACEUTICAL COMPOSITION CONTAINING A "LIMUS" FAMILY IMMUNOSUPPRESSIVE MACROLIDE
#1325Controlled-released peptide formulations
#1326AMORPHOUS AMBRISENTAN
#1327Method for producing preparations of substances poorly soluble in water
#1328Process for making dry and stable hemostatic compositions
#1329Therapeutic agent for spinal cord injuries
#1330Cancer cell targeting using nanoparticles
#1331Compositions and methods of delivery of pharmacological agents
#1332COMPOSITIONS FOR SITE-SPECIFIC DELIVERY OF IMATINIB AND METHODS OF USE
#1333Preparation of compositions with essentially noncrystalline embedded macrolide antibiotics
#1334MANUFACTURE OF TABLETS FROM ENERGY-APPLIED POWDER BLEND
#1335Manufacture of variable density dosage forms utilizing radiofrequency energy
#1336Small molecule inhibitors of ghrelin O-acyltransferase
#1337MULTI-LAYERED ORALLY DISINTEGRATING TABLET AND THE MANUFACTURE THEREOF
#1338SOLID COMPOSITION CONTAINING THE INGREDIENT RASAGILINE
#1339SOLID COMPOSITIONS
#1340PHARMACEUTICAL FORMULATION OF NANONISED FENOFIBRATE
#1341Dosage forms with improved bioavailability
#1342Solid dispersions containing kinase inhibitors
#1343PHARMACEUTICAL COMPOSITIONS COMPRISING COLLOIDAL SILICON DIOXIDE
#1344Compositions and methods of delivery of pharmacological agents
#1345Amphiphile prodrugs
#1346PHARMACEUTICAL COMPOSITIONS COMPRISING 5-CHLORO-N-(-METHYL)-2-THIOPHENCARBOXAMID
#1347CONTROLLED RELEASE NANOPARTICULATE CLOZAPINE COMPOSITIONS
#1348Pharmaceutical compositions providing enhanced drug concentrations
#1349FINELY PULVERIZED PHARMACEUTICAL COMPOSITION
#1350Therapeutic polymeric nanoparticle compositions with high glass transition temperature or high molecular weight copolymers
#1351Methods and compositions for localized agent delivery
#1352Galenic Formulations of Organic Compounds
#1353SOLID ORAL FORMULATIONS OF A PYRIDOPYRIMIDINONE
#1354Nanoporous foamed active compound-containing preparations based on pharmaceutically acceptable thermoplastically workable polymers
#1355Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus
#1356GABAPENTIN ENACARBIL COMPOSITIONS
#1357NOVEL EZETIMIBE FORMULATIONS
#1358PRECOMPACTED FAST-DISINTEGRATING FORMULATIONS OF COMPOUNDS WITH A LOW ORAL BIOAVAILABILITY
#1359Highly efficient and long-acting slow-release formulation of poorly soluble drugs and preparation method thereof
#1360PHARMACEUTICAL COMPOSITIONS FOR POORLY SOLUBLE DRUGS
#1361Methods and systems for generating nanoparticles
#1362Process for forming amorphous atorvastatin
#1363Solid ganaxolone formulations and methods for the making and use thereof
#1364Cancer cell targeting using nanoparticles
#1365Process for preparing snuff composition
#1366METHOD FOR PRODUCING POWDER CONTAINING NANOPARTICULATED SPARINGLY SOLUBLE DRUG, POWDER PRODUCED THEREBY AND PHARMACEUTICAL COMPOSITION CONTAINING SAME (As Amended)
#1367COMPOSITIONS FOR THE TREATMENT OF NEOPLASTIC DISEASES
#1368Oral Formulations of Chemotherapeutic Agents
#1369Formulation of silymarin with high efficacy and prolonged action and the preparation method thereof
#1370Stabilized tacrolimus composition
#1371STABILIZED SOLID DISPERSION OF ADEFOVIR DIPIVOXIL AND PREPARATION METHOD THEREOF
#1372PHARMACEUTICAL COMPOSITION FOR PREVENTING DYSBIOSIS ASSOCIATED WITH ENTERAL ADMINISTRATION OF ANTIBIOTICS
#1373INJECTABLE NANOPARTICULATE OLANZAPINE FORMULATIONS
#1374STABLE SOLID ORAL DOSAGE CO-FORMULATIONS
#1375Preparation of a powdery pharmaceutical composition by means of an extruder
#1376Methods and compositions of small molecule modulators of hepatocyte growth factor (scatter factor) activity
#1377Process for preparing microparticles
#1378PH-SENSITIVE SOLID PHARMACEUTICAL COMPOSITION FOR ORAL PREPARATION AND PREPARATION METHOD THEREOF
#1379Methods for micronization of hydrophobic drugs
#1380COMPOSITE ORGANIC COMPOUND POWDER FOR MEDICAL USE, METHOD FOR PRODUCING SAME AND SUSPENSION OF SAME
#1381LIQUID DOSAGE COMPOSITIONS OF STABLE NANOPARTICULATE ACTIVE AGENTS
#1382DIRECTLY PRESSED ALISKIREN TABLETS
#1383Pharmaceutical Composition for the Eradication of Helicobacter Pylori and Preparation Method Thereof
#1384STABILIZATION AND DELIVERY OF NUCLEIC ACID COMPLEXES
#1385NANOPARTICULATE BICALUTAMIDE FORMULATIONS
#1386MUCOADHESIVE PARTICULATE FORMULATION FOR INDUCING ANTIGEN-SPECIFIC IMMUNE TOLERANCE
#1387Pharmaceutical Compositions of Amorphous Atorvasta and Process for Preparing Same
#1388Controlled Release Dosage Form of Tacrolimus
#1389Implant devices that differ by release profile and methods of making and using same
#1390Amorphous Coprecipitates of Atorvastatin Pharmaceutically Acceptable Salts
#1391Microcrystalline cellulose compositions
#1392Carboxyvinyl polymer-containing nanoparticle suspensions
#1393Method for increasing bone density and/or reducing any osteochondral defects in an animal and a composition including vitamin K
#1394TUMORICIDAL, BACTERICIDAL, OR VIRICIDAL MACROPHAGE ACTIVATION
#1395Compositions comprising elemental metals
#1396Method of making a dry powder pharmaceutical composition
#1397Instrument and process for nanoparticles production in continuous flow mode
#1398Processes for the preparation of uracil derivatives
#1399METHODS OF INHIBITING THE FORMATION OF AMYLOID-BETA DIFFUSABLE LIGANDS USING ACYLHYDRAZIDE COMPOUNDS
#1400CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS
#1401Process for the preparation of a solid dosage form, in particular a tablet, for pharmaceutical use and process for the preparation of a precursor for a solid dosage form, in particular a tablet
#1402Ion exchange resin treated to control swelling
#1403Ion exchange resin treated to control swelling
#1404SOLID COMPOSITIONS COMPRISING AN OXADIAZOANTHRACENE COMPOUND AND METHODS OF MAKING AND USING THE SAME
#1405POLYMERIC PHEROMONE FORMULATION AND METHOD OF USE TO CALM STRESS-RELATED BEHAVIOR IN MAMMALS OVER AN EXTENDED PERIOD OF TIME
#1406NANOPARTICLES FOR TARGETED DELIVERY OF ACTIVE AGENTS TO THE LUNG
#1407Water-insoluble medicine
#1408ENHANCING SOLUBILITY AND DISSOLUTION RATE OF POORLY SOLUBLE DRUGS
#1409THERAPEUTIC COMPOSITIONS
#1410EXTRUDED ROD-SHAPED DEVICES FOR CONTROLLED RELEASE OF BIOLOGICAL SUBSTANCES TO HUMANS AND ANIMALS
#1411Nanoparticles for delivery of active agents
#1412Nanoparticles for delivery of active agents
#1413DRUG DELIVERY SYSTEM WITH STABILISING EFFECT
#1414Sustained release systems and preparation method thereof
#1415PROCESS FOR OBTAINING POWDER COMPOSITIONS OF ORLISTAT
#1416SOLID DOSAGE FORMS OF HIV PROTEASE INHIBITORS
#1417Nanoparticle carriers for drug administration and process for producing same
#1418Stabilisation of Proteins
#1419Compositions and methods for preparing and using same
#1420Second Generation Fatty Acid Compositions, Formulations, and Methods of Use and Synthesis Thereof
#1421PHARMACEUTICAL COMPOSITIONS FOR POORLY SOLUBLE DRUGS
#1422Solid Pharmaceutical Dosage Form
#1423Nanoparticulate statin formulations and novel statin combinations
#1424PHARMACEUTICAL COMPOSITION FOR POORLY SOLUBLE DRUGS
#1425Systems and methods for delivery of materials
#1426SOLUBILITY-ENHANCED FORMS OF APREPITANT AND PHARMACEUTICAL COMPOSITIONS THEREOF
#1427PARTICLES WITH INDUCIBLE CHANGE OF SHAPE
#1428NANOPARTICULATE COMPOSITIONS OF ANGIOGENESIS INHIBITORS
#1429ORAL CARE COMPOSITION FOR COMBATING DENTINE HYPERSENSITIVITY
#1430NANOPARTICULATE COMPOSITIONS OF ANGIOGENESIS INHIBITORS
#1431NANOPARTICULATE COMPOSITIONS OF ANGIOGENESIS INHIBITORS
#1432USE OF CIS-EPOXYEICOSANTRIENOIC ACIDS AND INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE TO REDUCE PULMONARY INFILTRATION BY NEUTROPHILS
#1433REDUCTION OF FLAKE-LIKE AGGREGATION IN NANOPARTICULATE ACTIVE AGENT COMPOSITIONS
#1434SOLID DISPERSIONS CONTAINING AN APOPTOSIS-PROMOTING AGENT
#1435Pharmaceutical dosage form for oral administration of a bcl 2 family inhibitor
#1436NANOPARTICULATE MELOXICAM FORMULATIONS
#1437Nanodispersion
#1438FORMULATION FOR ORAL ADMINISTRATION OF APOPTOSIS PROMOTER
#1439FORMULATIONS OF 1-(4-BENZOYL-PIPERAZIN-1-YL)-2-[4-METHOXY-7-(3-METHYL-[1,2,4]TRIAZOL-1-YL)-1H-PYRROLO[2,3-C]PYRIDIN-3-YL]-ETHANE-1,2-DIONE
#1440Methods and Compositions for Delivery of Medicaments to the Lungs
#1441SALTS OF ACTIVE INGREDIENTS WITH POLYMERIC COUNTER-IONS
#1442PROCESS FOR FORMING SOLID ORAL DOSAGE FORMS OF ANGIOTENSIN II RECEPTOR ANTAGONISTS
#1443Pharmaceutical Compositions
#1444NANOPARTICULATE MEGESTROL FORMULATIONS
#1445SLOW RELEASE BIOCIDAL THERMOPLASTIC COMPOSITIONS AND ARTICLES
#1446PHARMACEUTICAL COMPOSITION AND ADMINISTRATIONS THEREOF
#1447Pharmaceutical solid dispersions
#1448Pharmaceutical powder compositions
#1449Sterilization of dispersions of nanoparticulate active agents with gamma radiation
#1450Pharmaceutical Compositions and Methods of Using Same
#1451Compressed chewing gum tablet
#1452Pharmaceutically acceptable solubilizing composition and pharmaceutical dosage form containing same
#1453Method for the manufacture of stable, nano-sized particles
#1454GRAPE POLYPHENOLICS FOR PLATELET AND BACTERIAL CONTROL
#1455DOSAGE FORMS COMPRISING CELECOXIB PROVIDING BOTH RAPID AND SUSTAINED PAIN RELIEF
#1456MINERALIZED POLYMER PARTICLES AND THE METHOD FOR THEIR PRODUCTION
#1457Compositions and methods of delivery of pharmacological agents
#1458Nanoparticulate megestrol formulations
#1459PROCESS FOR THE PREPARATION OF CONTROLLED-RELEASE SOLID FORMULATIONS CONTAINING OXCARBAZEPINE, AND FORMULATIONS OBTAINABLE BY SAID PROCESS
#1460O-DESMETHYLVENLAFAXINE AND BAZEDOXIFENE COMBINATION PRODUCT AND USES THEREOF
#1461PHARMACEUTICAL COMPOSITIONS COMPRISING COLLOIDAL SILICON DIOXIDE
#1462Nanoparticulate azelnidipine formulations
#1463Method for producing microparticles and the microparticles
#1464Polyarylates for drug delivery and tissue engineering
#1465DRUG DELIVERY
#1466O-DESMETHYLVENLAFAXINE
#1467Compositions and methods of delivery of pharmacological agents
#1468COMBINATION FORMULATIONS
#1469PROCESS FOR PREPARING PARTICLES OF OPIOIDS AND COMPOSITIONS PRODUCED THEREBY
#1470PHARMACEUTICAL FORMULATION
#1471Method for the production of a medicament containing tadalafil
#1472In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate or nanoparticulate active agent compositions
#1473STABILIZED AMORPHOUS FORMS OF IMATINIB MESYLATE
#1474ANTIVIRAL COMPOSITIONS
#1475SOLID COMPOSITES OF A CALCIUM RECEPTOR-ACTIVE COMPOUND
#1476Administration form of osteogenic protein complexes
#1477Fine particles coated with lipid membrane
#1478Active Agent Formulations, Methods of Making, and Methods of Use
#1479METHOD FOR THE PREPARATION OF NANOPARTICLES CONTAINING A POORLY WATER-SOLUBLE PHARMACEUTICALLY ACTIVE COMPOUND
#1480PHARMACEUTICAL DOSAGE FORM FOR ORAL ADMINISTRATION OF TYROSINE KINASE INHIBITOR
#1481SOLIFENACIN COMPOSITIONS
#1482Nanoparticles comprising a cyclodextrin and a biologically active molecule and uses thereof
#1483SIMETHICONE SOLID ORAL DOSAGE FORM
#1484Iron(II)-Containing Treatments for Hyperphosphatemia
#1485Base for dry solid dispersion, solid dispersion containing the base, and composition containing the dispersion
#1486Delivery of a bioactive material
#1487Thyroid hormone analogs and methods of use
#1488SURFACE-TREATED MODAFINIL PARTICLES
#1489Pharmaceutical Compositions Containing Diacerein
#1490IMATINIB MESYLATE
#1491Process for the production of biodegradable, functionalised polymer particles and use thereof as pharmaceutical supports
#1492Small molecule inhibitors of ghrelin O-acyltransferase
#1493Method for treating infectious organisms normally considered to be resistant to an antimicrobial drug
#1494MODIFIED DOSAGE FORMS OF TACROLIMUS
#1495Formulation Comprising Fenofibric Acid, A Physiologically Acceptable Salt or Derivative Thereof
#1496THERAPEUTIC AGENT FOR SPINAL CORD INJURIES
#1497Process for the manufacture of a powder containing carotenoids
#1498Water-soluble compositions of bioactive lipophilic compounds
#1499Microstructural protein preparations containing adsorbed biologically active substances and their application in medicine and cosmetics
#1500NOVEL FORMULATIONS OF PHARMACOLOGICAL AGENTS, METHODS FOR THE PREPARATION THEREOF AND METHODS FOR THE USE THEREOF